I think this AIM stock has bags of potential

This AIM stock has been falling recently. But I think this is a buying opportunity. Here’s my view on the company.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Synairgen (LSE: SNG) is an AIM stock that has been undeniably volatile. But over the past month, the shares have fallen more than 30%. It’s a stark contrast from the 85% increase during the last 12 months. Of course, historical performance isn’t an indication of future returns.

The AIM stock is now trading around the 100p mark. I’d use this dip as a buying opportunity as I reckon this company still has bags of potential. Here’s why.

Why have Synairgen shares been falling?

I think the main reason why this AIM stock has fallen significantly is due to the successful rollout of Covid-19 vaccines.

It’s worth noting here that the stock rallied last year on the hopes of its SNG001 product. Unlike a vaccine, this is a treatment for coronavirus. So when there was doom and gloom about the pandemic, this stock soared after it announced that trials for SNG001 were successful.

In the UK the jabs have been rolled out to tens of millions of people, so the euphoria surrounding the AIM stock has subsided. I guess that early investors have also taken their profits.

Another reason why the shares have fallen is that the news flow regarding the treatment has somewhat reduced. The clinical trials for SNG001 will take time, but I’m optimistic for a positive outcome.

The potential

I think it’s important to realise that the pandemic isn’t over yet. While things in the UK may be improving, there are other countries that are still suffering the impact of Covid-19. And let’s not forget the threat of virus variants. For this reason, a treatment for coronavirus remains extremely important.

So far, SNG001 has proved successful in trials. It’s been tested on hospitalised Covid-19 patients as well as as people who are suffering from the illness at home and don’t require hospitalisation.

In its announcement at the end of April, CEO, Richard Marsden said the “SNG001 treatment led to a threefold likelihood of recovery to ‘no limitation of activities’ in the markedly/severely breathless population compared to those on placebo in the home and hospital setting, and that further analyses reinforce our previous findings”.

To me, this news is very encouraging. It’s also reassuring that international Phase III trials in hospitalised patients requiring supplemental oxygen are due to commence later this year.

Risks

Synairgen is making progress but still has a long way to go. There’s no guarantee that the Phase III trials will be successful. 

The company hasn’t made any sales yet and is unprofitable. There’s a lot riding on SNG001. And it could make or break Synairgen. This isn’t for the fainthearted. So I’d only invest what I could afford to lose.

For now, the company has enough cash to see it through further clinical trials. It managed to raise money last year and as of the end of 2020, Synairgen was sitting on a cash balance of £75m.

But if there are any setbacks, it may require further funding. And there’s no guarantee it will receive additional money. This could impact the stock.

My view

Despite these risks, I’d buy Synairgen shares at the current price. As a long-term investor, this company has bags of potential even after Covid-19. It’s research and findings could prove useful to another large firm. Hence the AIM stock could be a potential takeover target.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Nadia Yaqub has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

After it crashed 25%, should I buy this former stock market darling in my Stocks and Shares ISA?

Harvey Jones has a big hole in his Stocks and Shares ISA that he is keen to fill. Should he…

Read more »

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

How’s the dividend forecast looking for Legal & General shares in 2025 and beyond?

As a shareholder, I like to keep track of the potential dividend returns I could make from my Legal &…

Read more »

artificial intelligence investing algorithms
Investing Articles

Could buying this stock with a $7bn market cap be like investing in Nvidia in 2010?

Where might the next Nvidia-type stock be lurking in today's market? Our writer takes a look at one candidate with…

Read more »

Investing Articles

Is GSK a bargain now the share price is near 1,333p?

Biopharma company GSK looks like a decent stock to consider for the long term, so is today's lower share price…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Could December be a great month to buy UK shares?

Christopher Ruane sees some possible reasons to look for shares to buy in December -- but he'll be using the…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Sticking to FTSE shares, I’d still aim for a £1,000 monthly passive income like this!

By investing in blue-chip FTSE shares with proven business models, our writer hopes he can build sizeable passive income streams…

Read more »

Growth Shares

BT shares? I think there are much better UK stocks for the long term

Over the long term, many UK stocks have performed much better than BT. Here’s a look at two companies that…

Read more »

British Pennies on a Pound Note
Investing Articles

After a 540% rise, could this penny share keep going?

This penny share has seen mixed fortunes in recent years. Our writer looks ahead to some potentially exciting developments in…

Read more »